Clinical utility of targeted next generation sequencing in lung cancer
Carter, Mathew Ortega-Franco, Ana Rafee, Shereen Russell, Philip Halkyard, Emma Wallace, A. Lindsay, Colin R Blackhall, Fiona H
Carter, Mathew
Ortega-Franco, Ana
Rafee, Shereen
Russell, Philip
Halkyard, Emma
Wallace, A.
Lindsay, Colin R
Blackhall, Fiona H
Citations
Altmetric:
Abstract
Introduction: Somatic genotyping of single genes from tissue,
cytology and plasma circulating free DNA (cfDNA) is standard of care
in a subpopulation of advanced non-small cell lung cancer (NSCLC).
Recent developments in Next Generation Sequencing (NGS) provide
innovative opportunities to explore the broader genetic landscape
of lung cancer. Here, we sought to explore the clinical utility of
multigene testing beyond routine standard of care indications
and assess whether results were available in clinically relevant
timeframes.
Methods: Between 03 July and 20 September 2019, stage III and IV
patients with NSCLC and small cell lung cancer (SCLC) underwent
NGS via Foundation Medicine One testing from plasma (70 gene
panel) and formalin-fixed paraffin-embedded (FFPE) specimens
(324 gene panel) where sufficient material was available. Blood
collected in two Roche cell free DNA tubes and FFPE tissue with a
minimum neoplastic cell content of 20% was sent for central testing.
Results: 141 patients underwent NGS testing (113 NSCLC, 28 SCLC).
19/141 patients (13%) had both blood and FFPE tested and 123/141
(87%) had only blood tested. Results were available on 114/123 (93%)
blood samples. No clinically actionable mutations were identified in
6/114 (5%) blood samples, 4/114 (4%) yielded insufficient DNA, and
3/114 (3%) failed analysis. FFPE results were available in 18/19 (95%)
of patients, with one deemed insufficient for analysis. Median turnaround
time was 12 calendar days for blood (range 9–19 days) and 11
for tissue (range 7–17 days). Results led to an immediate treatment
change in 7/141 (5%) of patients, of whom 5 were enrolled onto a
clinical trial. Cases of interest will be discussed.
Conclusion: These data suggest that NGS testing can be undertaken in
clinically relevant time frames yielding results in 93% of our cohort. 5%
of patients were immediately linked to clinical trials, with additional
patients likely to be referred at subsequent lines or treatment.
Affiliation
Description
Date
2020
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Carter M, Ortega-Franco A, Rafee S, Russell P, Halkyard E, Wallace A, et al. Clinical utility of targeted next generation sequencing in lung cancer. Lung Cancer. 2020;139:S64-S